LitCovid-sentences  

PMC:7396557 / 32225-46106 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T249 0-57 Sentence denotes Relevant Information on the Clinical Application of LHQWC
T250 59-91 Sentence denotes Recommended Therapeutic Regimens
T251 92-230 Sentence denotes LHQWC has been recommended in 19 therapeutic regimens for treatment of COVID-19 in China (see detailed information in Tables 1 and 2 ).
T252 232-252 Sentence denotes Ingredients of LHQWC
T253 253-736 Sentence denotes Forsythia suspensa (Thunb.) Vahl (Lianqiao), Lonicera japonica Thunb. (Jinyinhua), Ephedra equisetina Bunge (Zhimahuang), Prunus armeniaca L. (Chaoxingren), Gypsum fibrosum (Shigao), Isatis tinctoria L. (Banlangen), Dryopteris crassirhizoma Nakai (Guanzhong), Houttuynia cordata Thunb. (Yuxingcao), Pogostemon cablin (Blanco) Benth. (Guanghuoxiang), Rheum palmatum L. (Dahuang), Rhodiola rosea L. (Hongjingtian), Mentholum (Bohenao), and Glycyrrhiza uralensis Fisch. ex DC. (Gancao).
T254 737-805 Sentence denotes Basic information on LHQWC is provided in the Supplementary Table .
T255 807-859 Sentence denotes Indications for the Treatment of COVID-19 With LHQWC
T256 860-996 Sentence denotes LHQWC is used during the clinical observation period of COVID-19, and wind-heat invading lung in early stage of the disease (mild case).
T257 997-1126 Sentence denotes The indicative symptoms are fever, mild aversion to cold, cough, weakness, headache and body pain, sore throat, and constipation.
T258 1128-1173 Sentence denotes Progress of Pharmacological Research on LHQWC
T259 1174-1372 Sentence denotes Modern pharmacological studies have shown that LHQWC has antiviral, immune-regulatory, anti-inflammatory, and antioxidant properties, efficacy against lung injury, and other effects (see Table 3 ).
T260 1373-1573 Sentence denotes LHQWC significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced the production of pro-inflammatory cytokines (TNF-α, IL-6, CCL-2/MCP-1, and CXCL-10/IP-10) at the mRNA level.
T261 1574-1660 Sentence denotes Furthermore, LHQWC treatment resulted in abnormal virion particle morphology in cells.
T262 1661-1792 Sentence denotes LHQWC significantly inhibits SARS-CoV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro (Li R.
T263 1793-1810 Sentence denotes F. et al., 2020).
T264 1811-2038 Sentence denotes In vitro experiments have shown significant antiviral activity against SARS-CoV, AIV H7N9, dual H1N1/H3N2, together with inhibition of Middle East Respiratory Syndrome (MERS)-CoV activity to a certain degree (Yao et al., 2020).
T265 2039-2269 Sentence denotes Yuewen Ding et al. used MTT and plaque reduction assays to show that LHQWC inhibited proliferation of multiple strains of influenza virus, and reduced virus titer and levels of inflammatory cytokines in the lungs of infected mice.
T266 2270-2428 Sentence denotes The results indicated that LHQWC acted as a broad-spectrum antiviral and, in particular, regulated the immune response to viral infection (Ding et al., 2017).
T267 2429-2653 Sentence denotes Qi Li et al. discovered that LHQWC not only reversed LPS-stimulated expression of macrophage chemotactic factor-1 (MCP-1) by macrophages, but also significantly improved pulmonary edema in a mouse model of acute lung injury.
T268 2654-2854 Sentence denotes Inhibition of expression and secretion of MCP-1 in lung tissues of model mice was accompanied by reduced infiltration of mononuclear macrophages and reduction of inflammatory injury (Li et al., 2019).
T269 2855-2979 Sentence denotes Fen Ping et al. studied the effects of LHQWC on rats with oxidative lung injury caused by fine particulate matters (PM 2.5).
T270 2980-3294 Sentence denotes The results showed that LHQWC significantly reduced lactate dehydrogenase (LDH) and malondialdehyde (MDA) serum levels in rats with lung injury, increased levels of glutathione peroxidase (GSH-Px), reduced pathological damage of lung tissues, and inhibited exudation of inflammatory cells into the alveolar cavity.
T271 3295-3418 Sentence denotes Together, the data indicated that LHQWC protected against oxidative stress injury in the lungs of rats (Ping et al., 2016).
T272 3419-3543 Sentence denotes Wenwen Cui et al. studied the impact of LHQWC in a mouse model of acute lung injury caused by intratracheal infusion of LPS.
T273 3544-3739 Sentence denotes LHQWC alleviated the inflammatory response in lung tissues by downregulating the IKK/IκB/nuclear factor (NF)-κB signaling pathway, thus, protecting mice from acute lung injury (Cui et al., 2016).
T274 3740-3925 Sentence denotes Siwen Tang et al. studied the effects of LHQWC intervention on pathological lung tissue injury in mice and expression of inflammatory cytokines caused by exposure to automobile exhaust.
T275 3926-4178 Sentence denotes The results showed that LHQWC reduced protein and mRNA expression of inflammatory cytokines in lung tissue by reducing blood levels of inflammatory cytokines, thus, protecting against lung tissue injury caused by automobile exhaust (Tang et al., 2015).
T276 4180-4206 Sentence denotes Clinical Research on LHQWC
T277 4207-4388 Sentence denotes Modern clinical studies have shown that LHQWC has therapeutic effects against viral diseases, such as COVID-19, SARS, MERS, influenza, and human infection with H7N9 avian influenza.
T278 4389-4505 Sentence denotes It can also be used to treat URI, chronic obstructive pulmonary disease (COPD) and other conditions (see Table 3 ).
T279 4506-5229 Sentence denotes LHQWC has been recommended in diagnosis and treatment schemes such as China’s SARS Diagnosis and Treatment Scheme (Version 2004) (Chinese Medical Association and China Association of Chinese Medicine, 2004), MERS Diagnosis and Treatment Scheme (Version 2015) (National Health and Family Planning Commission of People’s Republic of China, 2015), China’s Influenza Diagnosis and Treatment Scheme (Version 2019) (National Health Commission of the People's Republic of China and National Administration of Traditional Chinese Medicine, 2019), and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017) (National Health and Family Planning Commission of People's Republic of China, 2017).
T280 5230-5366 Sentence denotes Ke Hu et al. conducted a prospective multicenter open-label randomized controlled trial on LHQWC capsule in confirmed cases of COVID-19.
T281 5367-5511 Sentence denotes Patients (284) were randomized to receive usual treatment alone or in combination with LHQWC capsules (four capsules, thrice daily) for 14 days.
T282 5512-5593 Sentence denotes The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery.
T283 5594-5730 Sentence denotes The recovery rate was significantly higher in the combined treatment group compared with the control group (91.5% vs. 82.4%, p = 0.022).
T284 5731-5828 Sentence denotes The median time to symptom recovery was markedly shorter in the combined treatment group (median:
T285 5829-5855 Sentence denotes 7 vs. 10 days, p < 0.001).
T286 5856-6029 Sentence denotes Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in the combined treatment group (all p < 0.001).
T287 6030-6224 Sentence denotes The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, p < 0.001) and clinical cure (78.9% vs. 66.2%, p = 0.017) were also higher in the combined treatment group.
T288 6225-6341 Sentence denotes However, the two groups did not differ in the rate of conversion to severe cases or viral assay findings (p > 0.05).
T289 6342-6400 Sentence denotes No serious adverse events were reported (Hu et al., 2020).
T290 6401-6606 Sentence denotes Ruibing Lyu et al. conducted clinical research on 63 patients receiving conventional therapy in combination with LHQWC (treatment group) and 38 patients receiving only conventional therapy (control group).
T291 6607-6664 Sentence denotes Clinical data were collected 10 days after the treatment.
T292 6665-6879 Sentence denotes A comparison between the two groups was performed in terms of disappearance rates of cardinal symptoms (fever, cough, and weakness), duration of fever and disappearance rates of other individual symptoms and signs.
T293 6880-7087 Sentence denotes The disappearance rates of fever, cough, and weakness in the treatment group were 86.7%, 55.6%, and 82.5%, respectively, which were higher than those in the control group (67.7%, 30.6%, and 58.6%; p < 0.05).
T294 7088-7195 Sentence denotes The median duration of fever was 6 days in patients in the treatment group and 7 days in the control group.
T295 7196-7277 Sentence denotes There was no statistically significant difference between the groups (p = 0.171).
T296 7278-7427 Sentence denotes The disappearance rates of short breath and moist crackles (68.2% and 56.0%) were higher than those in the control group (20.0% and 20.0%, p < 0.05).
T297 7428-7595 Sentence denotes There were four cases of aggravation in the treatment group (6.4%) and six cases in the control group (15.8%), with no statistically significant difference (p > 0.05).
T298 7596-7678 Sentence denotes There were no obvious adverse reactions in the treatment group (Lyu et al., 2020).
T299 7679-7807 Sentence denotes Dezhong Cheng et al. conducted a multi-center retrospective analysis of the therapeutic effect of LHQWC in 51 COVID-19 patients.
T300 7808-7938 Sentence denotes The control group was treated with simple nutritional support, symptomatic treatment, antiviral therapy and antimicrobial therapy.
T301 7939-8061 Sentence denotes The treatment group was combined with LHQWC (6 g/bag) on the basis of the control group, one bag each time, 3 times a day.
T302 8062-8126 Sentence denotes The clinical data of patients treated for 7 days were collected.
T303 8127-8315 Sentence denotes The results showed that combined application of LHQWC significantly improved fever, weakness, cough, shortness of breath, chest distress, anorexia, and other clinical symptoms of COVID-19.
T304 8316-8495 Sentence denotes Improvements of the main symptoms and reduced incidence of the severe form suggested that LHQWC could be effective in the treatment of patients with COVID-19 (Cheng et al., 2020).
T305 8496-8620 Sentence denotes Ping Yu et al. conducted a study on the therapeutic effect of LHQWC combined with Abidole in the treatment of mild COVID-19.
T306 8621-8683 Sentence denotes A total of 295 patients were randomly divided into two groups.
T307 8684-8862 Sentence denotes The control group (n = 148) was treated with Abidole (0.2 g per day) orally, and the observation group (n = 147) was treated with LHQWC (6 g, thrice daily) combined with Abidole.
T308 8863-9118 Sentence denotes The results showed that the total effective rate of the observation group was significantly higher than that of the control group (80.95% vs 64.86%), and the rate of severe illness was significantly lower than that of the control group (14.29% vs 23.65%).
T309 9119-9507 Sentence denotes After 7 days of treatment, the scores for the main TCM syndromes (fever, fatigue, cough, dry throat, chest tightness) and the levels of C-reactive protein (CRP) and procalcitonin (PCT) in the observation group were significantly lower than those in the control group (p < 0.05), while white blood cells (WBC) and lymphocyte (LYM) were significantly higher than those in the control group.
T310 9508-9724 Sentence denotes The effective rate of chest computerized tomography (CT) in the observation group was 69.39%, which was higher than that in the control group (62.84%), but the difference was not statistically significant (p > 0.05).
T311 9725-9794 Sentence denotes There were no serious drug-related adverse reactions in either group.
T312 9795-10063 Sentence denotes The results show that LHQWC combined with Abidole can effectively relieve clinical symptoms in patients with mild COVID-19, regulate the expression of related inflammatory factors, improve the curative effect and reduce the rate of severe illness (Yu P. et al., 2020).
T313 10064-10174 Sentence denotes Lili Liu et al. conducted a retrospective analysis of the therapeutic effect of LHQWC in 32 COVID-19 patients.
T314 10175-10217 Sentence denotes The patients were divided into two groups:
T315 10218-10367 Sentence denotes Group A + L, in which 18 patients received Abidole (0.2 g, thrice daily) combined with LHQWC; and Group L, in which 14 patients received LHQWC alone.
T316 10368-10427 Sentence denotes During treatment there was one critical case in each group.
T317 10428-10533 Sentence denotes Abnormal liver function was observed in 14 cases (77.78%) in Group A + L and 8 cases (57.14%) in Group L.
T318 10534-10636 Sentence denotes Antibiotic treatment was applied in 17 cases (94.44%) in Group A + L and 13 cases (92.86%) in Group L.
T319 10637-10737 Sentence denotes Glucocorticoid use was reported in 10 cases (55.56%) in Group A + L and 9 cases (64.29%) in Group L.
T320 10738-11112 Sentence denotes Compared with Group L, significantly faster recovery of temperature (t = −2.471, p = 0.019), recovery of respiratory symptoms (t = −2.918, p = 0.007), chest CT inflammation absorption (t = −2.937, p = 0.006), time until two consecutive negative virus nucleic acid tests (t = −2.930, p = 0.006), and shorter hospital stay (t = −2.785, p = 0.009) were observed in Group A + L.
T321 11113-11246 Sentence denotes Abidor combined with LHQWC can be used to treat COVID-19, with good tolerance, to shorten the course of treatment (Liu et al., 2020).
T322 11247-11404 Sentence denotes Zhongping Duan et al. conducted a random, double-blind, and positive-drug parallel control clinical trial on the efficiency and safety of LHQWC against H1N1.
T323 11405-11483 Sentence denotes It was found that LHQWC reduced disease severity and the duration of symptoms.
T324 11484-11637 Sentence denotes The drug was also well tolerated, indicating that LHQWC might become an alternative therapeutic measure against H1N1 viral infection (Duan et al., 2011).
T325 11638-11879 Sentence denotes Pan Zhao et al. found by meta-analysis that LHQWC improved cough, sore throat, body ache, and other symptoms of patients infected with H1N1 virus, reduced the duration of fever, and was more effective than oseltamivir (Zhao P. et al., 2014).
T326 11880-12002 Sentence denotes Shiheng Wang et al. conducted a systematic review of the literature on efficacy and safety of LHQWC in treating viral flu.
T327 12003-12240 Sentence denotes The results showed that LHQWC gave a better total response rate, symptom improvement rate and body temperature recovery rate than the control group in treating viral flu, but consideration of its safety was important (Wang et al., 2019).
T328 12241-12531 Sentence denotes Li Tiehui et al. compared the clinical therapeutic effect of LHQWC and vitamin C Yinqiao Tablets in patients with URI, and found that LHQWC significantly improved nasal congestion, fever, headache, sore throat, weakness, aches in the limbs, intolerance of cold, and other clinical symptoms.
T329 12532-12617 Sentence denotes LHQWC had high efficacy and safety, and was therefore worthy of promotion (Li, 2019).
T330 12618-12867 Sentence denotes Dong Liang et al. conducted clinical research on 100 patients with COPD, and discovered that LHQWC improved conditions in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), especially those in the high risk subgroup.
T331 12868-12983 Sentence denotes The mode of action might be related to its ability to reduce release of inflammatory mediators (Dong et al., 2014).
T332 12985-13011 Sentence denotes Usage and Dosage of LHQWC:
T333 13012-13062 Sentence denotes Oral administration, four capsules, 3 times a day.
T334 13064-13090 Sentence denotes Adverse Reactions of LHQWC
T335 13091-13318 Sentence denotes Possible nausea, vomiting, diarrhea, stomach discomfort, heartburn, poor appetite, and other gastrointestinal adverse reactions; there might be abnormal liver function, palpitations or rash, and other side effects occasionally.
T336 13320-13337 Sentence denotes LHQWC Precautions
T337 13338-13394 Sentence denotes 1) Pregnant and lactating women should use with caution.
T338 13395-13535 Sentence denotes 2) It contains ephedrae herba (Mahuang), so should be used with caution by athletes and patients with high blood pressure and heart disease.
T339 13536-13640 Sentence denotes 3) Those with previous history of liver disease or with abnormal liver function should use with caution.
T340 13641-13800 Sentence denotes 4) It contains rheum, so the dose should be reduced appropriate in subjects who experience increased stool frequency and shapeless stools after administration.
T341 13801-13881 Sentence denotes 5) Nourishing traditional Chinese medicine should not be taken at the same time.